

August 7, 2013

AHS Laboratory Services Laboratory Integration, Standards & Initiatives Edmonton General Room 13R21, 11111 Jasper Ave Edmonton, AB T5K 0L4

Dear Physicians,

Re: Transition of *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC) Testing to Calgary Laboratory Services (CLS)

This letter is directed to all physicians and healthcare staff in South Zone East who currently submit samples for *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC) testing to the Medicine Hat Diagnostic Laboratory using Starplex sterile, screw-capped container or the cobas 4800 CT/NG Female Collection Kit.

We would like to inform you that as part of a provincial standardization and consolidation initiative; as of September 23<sup>rd</sup>, 2013 testing will be performed at Calgary Laboratory Services. Since the method that will be used; GEN-PROBE APTIMA COMBO2® Chlamydia/GC method is different than what is currently performed at Medicine Hat Diagnostic Laboratory, a change in the collection kit is required.

\*\*\*\* Please note: Urine samples must come already transferred in the urine specimen transport tube. Swab specimens must be collected with the blue shaft collection swab. Samples not collected properly will not be processed. \*\*\*\*

\*\*\*\* Please note as this assay is extremely sensitive, all individuals handling patient samples must ensure they avoid introducing contamination by changing gloves after each patient they come in contact with or after each patient sample they contact. \*\*\*\*

Included are the AHS/CLS Laboratory Bulletin, CLS utilization Memo and Newsletter, CLS Microbiology Requisitions, and Collection Instructions.

If you have any questions, please contact Medicine Hat Diagnostic Laboratory or Calgary Laboratory Services.

Sincerely,

Alberta Health Services

Basil Elyas, BSc, PMP, CSSBB Business Support Manager,

Laboratory Integration, Standards & Initiatives

Enc. 10

#### **MEMORANDUM**



TO: All Physicians

FROM: Dr. Dan Gregson, Division Head, Microbiology, CLS

**DATE:** AUGUST 7, 2013

RE: Testing of Women > 35 years of Age for Genital Chlamydia trachomatis/Neisseria

gonorrhoeae Cervicitis

As per the attached Calgary Laboratory Services (CLS) Microbiology Newsletter (August 2013), women ≥ 35 years of age will no longer be routinely tested for genital *Chlamydia trachomatis/Neisseria gonorrhoeae* cervicitis effective September 23, 2013 when CLS assumes responsibility for testing Medicine Hat patients.

CLS will routinely test women in this age group in the following clinical situations:

- 1) Woman meets the **risk factors** outlined by Health Canada which include:
  - Recent contact with a known case of sexually transmitted infection (STI) and/or
  - Sexually active with new or > 2 partners within the past 6 months and/or
  - Street involvement and/or
  - Substance abuse
  - Approval by Microbiologist-on-Call
- 2) Woman has symptoms suggestive of cervicitis and/or urethritis
- 3) Pregnant prenatal screening. Public Health requires routine screening of pregnant women for genital *Chlamydia trachomatis* and/or *Neisseria gonorrhoeae* infection. CLS will therefore continue to routinely screen pregnant women, regardless of age.

Physicians should complete the clinical history on the CLS Microbiology requisition, indicating why a woman  $\geq$  35 years of age is being tested as outlined above. If the clinical reason for testing is not provided, the sample will not be analyzed.

CLS holds all genital specimens from women  $\geq$  35 years of age for 7 days that are initially rejected for testing because a clinical history is not provided on the requisition. In these cases, the Medical Microbiologist-on-Call should be contacted at 403-770-3757 to have the testing approved.

If you have any questions or concerns, please contact the Medical Microbiologist on call at: 403-770-3757.

August 2013 CLS Memo

## MICROBIOLOGY NEWSLETTER

Dr. D. Gregson - Editor Dr. D. Church - Author August 2013

# Calgary Zone – Epidemiology of Genital *Chlamydia trachomatis* (CT) Infection in Women and Rationale for Restricted Testing in Those ≥ 35 Years of Age

Calgary Laboratory Services (CLS) currently performs simultaneous routine testing for both genital CT and *Neisseria gonorrhoeae* (GC) infection from urethral and endocervical swabs or urine from females using an automated nucleic acid amplification test called the APTIMA COMBO 2® Assay, which is run on the TIGRIS instrument (Hologic, Gen-Probe, San Diego, CA). This assay has a reported sensitivity and specificity of 94.2% and 97.6% respectively for both swabs and urine samples (<a href="http://www.gen-probe.com/products-services/aptima-combo">http://www.gen-probe.com/products-services/aptima-combo</a>).

CLS implemented a new policy in the Calgary Zone in March 2003 that restricted routine testing of genital samples for CT and GC infection in women $\geq$ 35 years of age. The Microbiology requisition was changed so that physicians had to provide a history for genital samples from women $\geq$ 35 years to be automatically tested as follows:
□ Symptoms
□ At Risk
□ Pregnant
This newsletter outlined the rationale for implementing the age-restricted testing policy for women $\geq$ 35 years of age.

#### 1) Who is at risk for acquiring genital CT infection?

Guidelines have been published by Health Canada that outline who is at risk for acquiring genital CT infection<sup>1</sup>. The following patients have a high risk for acquiring genital CT infection and should be routinely tested for the presence of infection: 1) sexually active males and females <25 years of age, and/or 2) recent contact with a known case of any sexually transmitted infection (STI), and/or 3) sexually active with new or >2 partners in the past 6 months, and/or 4) street involved, and/or 5) involved in any substance use.


# 2) Demographics and prevalence of genital CT infection in women being tested for genital CT infection by CLS:


Figure 1 shows the number of negative versus positive genital CT tests done by CLS for women during the years of 2001-02 and according to age groups before testing was restricted to women  $\leq$  35 years of age. Figure 2 shows that after the age of 30-years, the overall rate of genital CT infection in women falls to an almost negligible rate of 0.5%. The peak overall prevalence of genital CT infection in women occurs in those between the ages of 21-30 years, and confirmed genital infection sharply decreased in women older than 30 years of age. Although much less prevalent than genital CT infection, the demographics of genital GC infection are similar (data not shown). This data confirmed that CLS was unnecessarily routinely testing many older women without any risk prior to the implementation of the age-restricted testing policy<sup>2, 3</sup>. A recent review of the testing data in our region from last year showed that the prevalence of CT infection amongst women has not changed, except more testing is now being done in girls and teens  $\leq$  15 years of age.

Newsletter, August 2013

Figure 1. Numbers of CT Negative versus Positive Genital CT Tests on Women - CLS 2001-02

Figure 2. Proportion of Women with Positive Genital CT Tests
- CLS 2001-02





#### 3) What is the Risk Factor Profile of women being tested for genital CT infection in Calgary?

Several regional studies were also done prior to implementation of our age-restricted testing policy to determine the reasons why women in Calgary were being tested for genital CT infection<sup>2, 3</sup>. Women aged 15 to 75 years were enrolled at various patient care locations in the Calgary Health Region. Pertinent risk factors for genital CT infection were recorded and a gynecological examination was performed. Two endocervical swabs and a first-void urine sample were collected for CT detection using two different nucleic acid amplification methods<sup>2</sup>. Five hundred and four women with a mean age of  $28.1 \pm 8.22$  years were enrolled from the Provincial STI clinic, the family planning clinic, the infertility clinic, and at the Emergency Departments and physicians' office practices. Two hundred ninety-one women (57.8%) were at high risk for acquiring genital CT infection. Twenty-eight (5.6%) tested positive for CT infection and almost all of these women (26 of 28.9%) had risk factors for acquiring infection. Of the high-risk women, 9.8% were CT positive versus only 1.3% of the women were at low risk (P=0.0001). Only two of 152 (1.3%) of the women > 30 years had genital CT infection. Although most women were asymptomatic, those with laboratory-confirmed CT infection were more likely to have genitourinary symptoms. Three hundred forty-three of 476 (72%) of the women who did not have genital CT infection had no risk factors, and screening was done as part of a routine gynecological examination for other purposes (prenatal visit, Pap smear)<sup>3</sup>.

#### 4) References:

- Canadian Guidelines on Sexually Transmitted Infections Updated January 2010. Chlamydial Infections-Section 5-Management and Treatment of Specific Infections. Canada: Public Health Agency of Canada, 2013. <a href="http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-2-eng.php">http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-2-eng.php</a>
- 2. Semeniuk H, A Zentner, R Read and DL Church. Evaluation of sequential testing strategies using non-amplified and amplified methods for detection of *Chlamydia trachomatis* in endocervical and urine specimens from women. Diag Microbiol Inf Dis 2002; 42:43-57.
- 3. Church DL, Amante L., H Semeniuk, Gregson DB. Selective testing of women based on age for genital Chlamydia trachomatis and Neisseria gonorrhoeae infection in a centralized regional microbiology laboratory. Diagn Microbiol Infect Dis. 2007, Apr; 57 (4): 379-85. Epub 2007 Jan 19.

## IF YOU HAVE ANY QUESTIONS OR CONCERNS PLEASE CONTACT:

Dr. Dan Gregson, Clinical Section Chief, Microbiology at: 403-770-3762, Sandra Corbett, Manager of Microbiology at: 403-770-3215 or the Microbiologist-on-Call at CLS at: 403-770-3757

Newsletter, August 2013 2





#### **Microbiology Requisition Requirements:** Chlamydia trachomatis/Neisseria gonorrheae Testing

REQUIRED INFORMATION

Date & Time Collected:

Date and time

the specimen was collected

is required

#### Benefits of providing CLS with COMPLETE and LEGIBLE information:

- Promotes patient safety through reduced transcription errors
- Ensures samples are processed for the correct patient and tests are sent to the correct provider
- Reduces turn around time when processing patient samples

The two letter province code and Personal Health

Ordering physician is required for laboratory standards. ✓ Please stamp all requisitions with the physician's stamp provided by CLS

Number ensure accurate patient identification and Patient's registration full legal name, ORDERING PHYSICIAN DOT REQUISITION complete OVER FOR ADDIT a Health additional ERSONAL HEALTH NUMBER (PHN) address. "COPY Dr. Fred Smith AB 4 5 - 6 7 8 gender, **All Smiles Med Clinic** date of TO" **Patient** Example 222-456 Happy Dr. SW birth, and reports 22 Happy Way SE Calgary, AB phone are number Cole Jonathan Market Mall GENDER DATE OF BIRTH PAT). needed ensure 1988 / May 40 5 nfection Diagnosis/Suspected Organism Antibiotics last name, accurate first name patient IMMUNOSUPPRESSED. | YES | NO NEUTROPENIC. | YES | NO MOUTH/NOSE/THROAT/RESPIRATORY/EYE ID and URINE/STOOL Candida/Vincent's
Herpes (HSV) DFA slide req'd ☐ Bacterial Culture (C & S)☐ Candida/Yeast ☐ Mouth/Gingiva/Tongue ☐ Urine - Midstream (MSU) location ☐ Urine - Catheter S. aureus screen OR ☐ Nose/Nasal ☐ Urine - Other specify source: are □ Chlamydia/GC
□ less than 35 years old
□ Symptomatic/At Risk
□ Pregnant
□ Planning Pregnancy MRSA screen ☐ Urine - collect initial stream Testing only performed when Nasopharyngeal (specify): required □ aspirate □ wash □ swab history provided at right ☐ Group A Strep (GAS) ☐ Allergy to Penicillin/Rx Failure M THROAT ☐ Stool Bacterial Culture (C & S) ☐ Other - specify: stridium difficile toxin ☐ Throat Cystic fibrosis (CF) - ACH ☐ CF Protocol M THROATCE ☐ Stool · Giardia/Cryptosp Glardia/Cryptosporidium Screen Patient history not required □ Bacterial Culture (C & S) IM SPUTUM IM SPUTUM Screen only ☐ E-tube aspirate □ Candida/Yeast ☐ Stool - Full Ova & Parasi Full O & P ☐ T-tube aspirate RO YEAST ☐ Fungal Culture
☐ Adult CF Protocol IM FUNGAL ☐ Sputum Cystic Fibrosis Always indicate specimen site ☐ Pediatric CF Protocol and source where applicable ☐ Bronchoalveolar lavage (BAL)
☐ Bronchial Wash (BW) □ Bacterial Culture (C & S) M BAL M BW Include patient history when UROGENITAL: For surgical/traumatic urogenital wounds/abscesses complete superficial wound section requested on the requisition ☐ Cervical or ☐ Vaginal vault >35 years old testing only □ Chlamydia/GC -[M CHLAMGC] to ensure appropriate testing ☐ Symptomatic/At Risk performed when history □ Pregnant is performed ☐ Planning Pregnancy provided at right GC Culture:Treatment failure only □ Cervical or □ Vaginal v? [M GC 1ycoplasma/Ureaplasma □ Vaginal/Adult (13 vr 'ast □ Vaginal vault \_\_\_nas vaginalis lycoplasma/Ureaplasma oxic shock syndrome

2013 - August

Always indicate

specimen site and source where applicable

Include patient history

when requested on the

requisition to ensure appropriate testing is performed

FOR INFORMATIO	N ON SPECIMEN COL		I, STOR	AGE AN			www.calgarylal	bservices	.com
Alberta Health	Laboratory					SEE OVER FOR ADD	ITIONAL INFORMATION		
Services	(Арргу ОДО ВТ. ОПТО		PROVINCE		PERSONAL	HEALTH NUMBER (PI	HN)	REGIONAL I	HEALTH RECORD
	Last Name / Full First	Name:	DATIFALT					_	
	5 Digit Client #:		PATIENT LA	AST NAME		FULL FIR	RST NAME	MIDDLI	E NAME
	Alpha Suffix Provider		PATIENT AL	DDRESS			CITY, PROVINCE		POSTAL CODE
COPY TO			-				,		
1)			CHART NU	MBER	GENDER	DATE OF BIRTH		PATIENT PHO	NE NUMBER
Last Name Infection Diagnosis/Suspected Organical		ress/Location	-			YYYY	/ /	-   _	
			LIST TESTS	REQUIRED	STAT (SEE R	EVERSE FOR TESTS	AVAILABLE STAT)	\(/	
IMMUNOSUPPRESSED- ☐ YES [		S □ NO							
MOUTH/ NOSE/THROAT/RESPII  ☐ Mouth/Gingiva/Tongue	RATORY/EYE  Candida/Vincent's	[M MOUTH]		URINE/ST  ☐ Urine -	Midstream	(MSU)	□ Bacterial Culture (	C & S)	[M URINE]
□ Nose/Nasal	☐ Herpes (HSV) DFA slide req'd☐ S. aureus screen☐	[M HDFA]		☐ Urine - Catheter			☐ Candida/Yeast	<u> </u>	[M URINE
	☐ MRSA screen OR	[M MRSA]		☐ Urine - Other specify source: ☐ Urine - collect initial stream			☐ Chlamydia/GC	F:R/O YEAST] [M CHLAMGC	
Nasopharyngeal (specify):  ☐ aspirate ☐ wash ☐ swab	□ RSV	[M RRSV]		Testing only performed when history provided at right			☐ less than 35 ye.☐ Symptomatic/A		
□ Throat	☐ Group A Strep (GAS) ☐ Allergy to Penicillin	[M BETA] [M BETA]					☐ Pregnant☐ Planning Pregn		
	☐ Rx Failure/Other - specify:	F: PEN ALLEI		□ Stool			☐ Bacterial Culture (C & S)		[M STOOL]
☐ Throat Cystic fibrosis (CF)	□ CF Protocol	F: R/O	<u>-</u> ]				☐ Clostridium difficile toxin☐ Rotavirus		[M CDIFF] [M ROTA]
(ACH only)		•		☐ Stool - Giardia/Cryptosporidiur Screen only			☐ Giardia/Cryptospo Patient history not	[M GIACRY]	
☐ Sputum ☐ E-tube aspirate	<ul><li>□ Bacterial Culture (C &amp; S)</li><li>□ Candida/Yeast</li></ul>	[M SPUTUM] [M SPUTUM		□ Stool - I	Full Ova &	Parasite (O &P)	□ Full O & P		[M OP]
☐ T-tube aspirate	☐ Fungal Culture	F: R/O YEAST	Γ]		only perfor provided at		☐ Travel to	туріо зстеет	
□ Sputum Cystic Fibrosis	☐ Adult CF Protocol	[M SPUTUMO	CF]	Note: Diarrhea	a is not an a	acceptable history	<ul><li>□ Travel Clinic</li><li>□ Gl Consultation</li></ul>	/patient	
(FMC and ACH only)  ☐ Bronchoalveolar lavage (BAL)	☐ Pediatric CF Protocol☐ Bacterial Culture (C & S)	[M BAL]					☐ Immigration☐ Immunosuppres		
☐ Bronchial Wash (BW)	, ,	[M BW]		MISCELLANEOUS PARASITES/EC			☐ Bloody stool		
☐ Bronchoalveolar lavage (BAL) - CF patient	- □ CF Protocol	[M BAL] F: CF Protoco	oll	□ Specify source:		ARASITES/ECTOP	□ Pinworm		[M PIN]
Specify sites:	☐ Candida/Yeast		: R/O YEAST ]		☐ Ectoparasite ☐ Other - spec			n	[M PID]
	☐ Fungal Culture	[M FUNGAL]		EAR □ Ear □ Left □ Right			□ Bacterial Culture (	C & C)	[M EAR]
	☐ PCP - BAL only ☐ Legionella Culture - BAL only	[M PCP]		Indicat	te Myringot	omy Tubes:	Dacterial Culture (	C & 3)	[W LAT
	☐ Other - specify:	[M LLGO]		SUPERFIC		IDS/ULCERS			
□ Protected Brush (PBS)	□ Bacterial Culture (C & S)	[M PBS]		l	ecify sourc		☐ Bacterial Culture (☐ Candida/Yeast	C & S)	[M WOUND]
□ Eye □ Left □ Right	includes anaerobic culture  □ Bacterial Culture (C & S)	[M EYE]		□ Superfic		swab (<1 cm deep)			F: R/O YEAST]
☐ Conjunctival swab☐ Corneal swab	☐ Chlamydia/GC	[M CHLAMGO	C]	☐ Other - specify:			☐ Herpes (HSV) DFA	Olida nasi'd	IM HDEA1
	☐ Herpes (HSV) DFA slide req'd	[M HDFA]		SURGICA	SURGICAL SPECIMEN/IN		EVICE/DEEP WOUND/A	BSCESS/CAT	HETER TIP
☐ Eye: Critical ☐ Left ☐ Right	☐ Other - specify: ☐ Bacterial Culture (C & S)	[M EYECRITI	]	i	ecify sourc		☐ Bacterial Culture ( ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	C & S) ID][M TISSUE	[M WOUND]
☐ Vitreous/Aqueous Eye Fluid☐ Corneal scraping/Ulcer	☐ Fungal Culture	[M FUNGAL]		☐ Deep wound swab (>1 cm deep) ☐ Deep abscess			☐ Anaerobic culture includes aerobic c	(C & S)	[M ANO2]
☐ Orbital fluid	☐ Herpes (HSV) DFA slide req'd☐ Acanthamoeba	[M ACANTH]		☐ Aspirat		sthetic joint	☐ Candida/Yeast	, and a	[F: R/O YEAST
☐ Other - specify: UROGENITAL: For surgical/	 traumatic urogenital wounds/ab	scesses		□ Implant	ted device	ou lette jon t	☐ Fungal Culture [M F		[M FUNGAL]
complete su	perficial wound section  Chlamydia/GC -	[M CHLAMGO	01	□ Other -	er Tip/site:		☐ Bacterial Culture (	C & S)	[M TIP]
>35 years old testing only	☐ Symptomatic/At Risk	[IN CHLAMGO	<b>J</b>		•		□ Candida/Yeast	•	[M TIP F: R/O YEAST]
performed when history provided at right	<ul><li>□ Pregnant</li><li>□ Planning Pregnancy</li></ul>				TERILE FLU	JIDS	Dontonio I Monoto Con	lt	[M BLOOD]
☐ Cervical or ☐ Vaginal vault	☐ GC Culture:Treatment failure only			Blood Cu ☐ Periphe	eral		<ul><li>□ Bacterial/Yeast Cu</li><li>□ Indicate if Endoca</li></ul>		[IN BLOOD]
☐ Vaginal/Adult (13 yrs or older) or	□ Mycoplasma/Ureaplasma □ BV/Yeast	[M MU] [M BV/YST]		☐ Central☐ Arterial☐					
□ Vaginal vault	☐ Trichomonas vaginalis	[M TRICH			access li				[M Malaria]
	<ul><li>☐ Mycoplasma/Ureaplasma</li><li>☐ Toxic shock syndrome</li></ul>	[M MU] [M UROGEN]	<u> </u>	<ul> <li>□ Malaria: History form re</li> <li>□ Other blood parasites:</li> </ul>					
Dedictric (less than 12 yes)		F:			spinal fluic	d (CSF):	☐ Bacterial Culture (	C & S)	[M CSF] [M ANO2]
☐ Pediatric (less than 13 yrs) ☐ Vaginal ☐ introitus	☐ Bacterial Culture (C & S)	[M UROGEN]	J	□ Indwell	ing CNS S		☐ Fungal Culture		[M FUNGAL]
☐ Pediatric (less than 13 yrs) ☐ Rectal ☐ Perianal ☐ Perineum	☐ R/O Group A Strep (GAS) ☐ R/O S. aureus	[M WOUND F: R/O	_]	□ Other -	specify:				
☐ Pediatric (less than 13 yrs)	☐ R/O Candida/Yeast☐ Chlamydia/GC	[M CHLAMG(	 C]	☐ Peritoneal dialysis fluid (dialysate			☐ Bacterial Culture (	C & S)	[M FLUID] [M ANO2]
☐ Vaginal ☐ Urethral ☐ Řectal ☐ Urethra (13 yrs or older)	□ Chlamydia/GC	[M CHLAMGO		□ Pleural	fluid		includes aerobic culture includes aerobic c	ulture	F: R/O YEAST
(12 )12 31 41431)	☐ Mycoplasma/Ureaplasma ☐ GC Culture: Treatment failure only	[M MU] [M GC]		□ Synovia □ Fluid - 0	al fluid other spec	ify:	□ Fungal Culture		[M FUNGAL]
☐ Rectal Adult (13 yrs or older)	☐ GC Culture	[M GC]	01	Other test requests require Microbiologic			logist On Call approva	al 403-770-37	57
□ Vaginal/Rectal - pregnant only	☐ ChlamydiaGC ☐ Group B Streptococcus (GBS)			1	1	ų. 1	3		
□ Semen □ Genital ulcer	☐ Bacterial Culture (C & S) ☐ Herpes (HSV) DFA slide req'd	[M UROGEN]		Date & Ti-	me Collect		RED INFORMATION Collected by:		
Specify source: DERMATOPHYTES	- 1101poo (1101) DI A silue 184 u	[W LIDI A]		Date & III		.cu.	Jonetteu by.		
Specify source:	☐ Fungal Culture/KOH	[M FUNGAL]		Accession	n Number(s	<u> </u>			
☐ Skin ☐ Hair ☐ Nails		<u> </u>							

## Calgary Laboratory Services

Mailing Address: Diagnostic & Scientific Centre 9, 3535 Research Road N.W. • Calgary, Alberta • T2L 2K8 Main Reception 403-770-3500 Laboratory Information Centre 403-770-3600 • www.calgarylabservices.com

#### PATIENT SERVICE CENTRES – APPOINTMENTS ARE STRONGLY RECOMMENDED. WEBSITE BOOKING: www.calgarylabservices.com OR CALL 403-770-5136

General Information or Inquiries: www.calgarylabservices.com or call Lab Information Centre 403-770-3600

Medical Staff: For test information, specimen collection instructions, etc. see www.calgarylabservices.com Physicians may contact the Laboratory Information Centre (L.I.C.) for test results and related inquiries

CENTRAL (Downtown) CALGARY	NORTHWEST CALGARY	SOUTHEAST CALGARY	NORTHEAST CALGARY		
☐ Gulf Canada Square 344 - 401 - 9 Avenue SW Fax: 403-777-5148 Mon - Fri 7:00 am - 4:30 pm ☐ Sheldon Chumir Health Centre 1213 - 4th Street SW Fax: 403-955-6199 Mon - Fri 7:00 am - 4:30 pm	■ Beddington Towne Centre 209 - 8120 Beddington Blvd NW Fax: 403-777-5137 Mon - Fri 6:30 am - 6:00 pm Sat 7:00 am - 3:00 pm ■ Ranchlands 150 - 1829 Ranchlands Blvd NW Fax: 403-777-5140 Mon - Fri 6:30 am - 4:00 pm Sat 7:00 am - 3:00 pm	Avenida Village 12445 Lake Fraser Dr SE Fax: 403-777-5176 Mon - Fri 6:30 am - 4:00 pm  South Calgary Health Centre 211 - 31 Sunpark Plaza SE South Entrance Fax: 403-777-5186 Mon - Fri 6:30 am - 6:00 pm Sat/Sun/Holidays 7:00 am - 3:00 pm	Marlborough #455 - Marlborough Mall Prof. Towe 433 Marlborough Way NE Fax: 403-777-5146 Mon - Fri 6:30 am - 4:00 pm Sat 7:00 am - 3:00 pm McKnight Village 5426 Falsbridge Drive NE Fax: 403-777-5183 Mon - Fri 6:30 am - 4:00 pm Sat 7:00 am - 3:00 pm		
Glenmore Landing D264 - 1600 - 90 Avenue SW Fax: 403-777-5166 Mon - Fri 7:00 am - 4:30 pm  Glenbrook Plaza 154 - 3715 - 51 Street SW Fax: 403-777-5182 Mon - Fri 6:30 am - 6:00 pm Sat 7:00 am - 3:00 pm	Stadium Foothills Professional Building 160 - 1620 - 29 Street NW Fax: 403-777-5134 Mon - Fri 7:00 am - 4:30 pm  Market Mall Prof. Centre 300 - 4935 - 40 Avenue NW Fax: 403-247-6672 Mon - Fri 6:30 am - 6:00 pm Sat/Sun 7:00 am - 3:00 pm	Riverbend 180 - 200 Rivercrest Drive SE (Riverbend Atrium) Fax: 403-777-5156 Mon - Fri 7:00 am - 4:30 pm  South Health Campus 4448 Front Street SE Opening Fall 2012	Sat 7:00 am - 3:00 pm  Sunridge 3 - 2681 - 36 Street NE Fax: 403-777-5155 Mon - Fri 6:30 am - 6:00 pm Sat/Sun 7:00 am - 3:00 pm  Airdrie Community Health Centre 103 - 217 Centre Avenue SW Airdrie, AB Fax: 403-948-4064 Mon - Fri 7:00 am - 4:30 pm		
Sloane Square 210 - 5920 - 1A Street SW Fax: 403-777-5162 Mon - Fri 7:00 am - 4:30 pm Sat 7:00 am - 3:00 pm	North Hill #254 North Hill Shopping Centre 1632 - 14 Avenue NW Fax: 403-777-5127 Mon - Fri 7:00 am - 4:30 pm		Cochrane Community Health Centre 60 Grande Blvd Cochrane, AB Fax: 403-932-5441 Mon - Fri 7:00 am - 4:30 pm		

For Calgary Rural Laboratory locations and hours of operation, visit http://www.calgarylabservices.com/lab-patient/lab-locations/rural-lab-locations.aspx

Alberta Health Care or other form of government issued I.D. must be presented at each visit

#### CALGARY REGION HOSPITAL LABORATORY LOCATIONS

Alberta Children's Hospital Mon-Fri 7:30 am - 5:00 pm

**Peter Lougheed Centre** Mon-Fri 7:00 am - 5:00 pm

**Rockyview General Hospital** Mon-Fri 6:30 am - 5:00 pm

#### **FOOTHILLS MEDICAL CENTRE**

Special Services Building Ground Floor SSB - Room AGC72C Mon-Fri 7:30 am - 4:00 pm Womens Health Centre Room 127 North Tower Mon-Fri 7:00 am - 4:00 pm

## Microbiology Tests Available STAT

Gram stain

Malarial Smear

Pneumocystis jiroveci (PCP)

Other tests ordered STAT require the approval of a Microbiologist. Contact: MICROBIOLOGIST ON CALL 403-770-3757 (Physicians Only)

For General Laboratory tests available STAT refer to the vellow Community General Requisition (9012PSC). or the Acute Care Requisition (9011RRL)

**GEN-PROBE** 



### Collection for Male and Female Urine Specimens

Patient should not have urinated for at least 1 hour prior to specimen collection.

- 1. Direct patient to provide first-catch urine (approximately 20 to 30 mL of initial urine stream) into urine collection cup free of any preservatives. Collection of larger volumes of urine may result in specimen dilution that may reduce test sensitivity. Female patients should not cleanse labial area prior to providing specimen.
- 2. Remove cap from urine specimen transport tube and transfer 2 mL of urine into urine specimen transport tube using disposable pipette provided. The correct volume of urine has been added when fluid level is between black fill lines on urine specimen transport tube label.
- 3. Re-cap urine specimen transport tube tightly. This is now known as the "processed urine specimen."

## **Specimen Transport and Storage**

- 1. After collection, transport and store the processed urine specimens in the APTIMA urine specimen transport tube at 2°C to 30°C until tested. Processed urine specimens should be assayed with the APTIMA Assay for CT and/or GC within 30 days of collection. If longer storage is needed, freeze at -20°C to -70°C for up to 90 days after collection.
- 2. Urine samples that are still in the primary collection container must be transported to the lab at 2°C to 30°C. Transfer urine sample into APTIMA urine specimen transport tube within 24 hours of collection. Store at 2°C to 30°C and test within 30 days of collection.







GEN-PROBE

### Collection for Endocervical Swab Specimens

- 1. Remove excess mucus from cervical os and surrounding mucosa using cleaning swab (white shaft swab in package with red printing). Discard this swab.
  - A large-tipped cleaning swab (not provided) may be used to remove excess mucus.
- 2. Insert specimen collection swab (blue shaft swab in package with green printing) into endocervical canal.
- 3. Gently rotate swab clockwise for 10 to 30 seconds in endocervical canal to ensure adequate sampling.
- 4. Withdraw swab carefully; avoid any contact with vaginal mucosa.
- 5. Remove cap from swab specimen transport tube and immediately place specimen collection swab into specimen transport tube.
- 6. Carefully break swab shaft at scoreline; use care to avoid splashing contents.
- 7. Re-cap swab specimen transport tube tightly.

#### Collection for Male Urethral Swab Specimens

Patient should not have urinated for at least 1 hour prior to specimen collection.


- 1. Insert specimen collection swab (blue shaft swab in package with green printing) 2 to 4 cm into urethra.
- 2. Gently rotate swab clockwise for 2 to 3 seconds in urethra to ensure adequate sampling.
- 3. Withdraw swab carefully.
- 4. Remove cap from swab specimen transport tube and immediately place specimen collection swab into specimen transport tube.
- 5. Carefully break swab shaft at scoreline; use care to avoid splashing contents.
- 6. Re-cap swab specimen transport tube tightly.

### **Specimen Transport and Storage**

After collection, transport and store swab in swab specimen transport tube at 2°C to 30°C until tested. Specimens must be assayed with the APTIMA Assay for CT and/or GC within 60 days of collection. If longer storage is needed, freeze at -20°C to -70°C for up to 90 days after collection.







PROCEDURE GUIDE COLLECTION



Unisex Swab Specimen Collection

for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC)



Improper Sample Collection Results In Sample Rejection

